drugset
drugset / Trial / NCT04749394

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

NCT04749394 ↗

Phase 2 Unknown 42 enrolled Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

This is a phase II, open-Label, multi-centre study to determine the efficacy and safety of Camrelizumab plus apatinib in participants with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), who have not progressed following platinum-based concurrent chemoradiation therapy (cCRT) or sequential chemoradiation therapy (sCRT). This study will be conducted in China mainland.

Timeline

Start
2021-03-17
Primary completion
2025-01
Completion
2025-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Rivoceranib Small molecule 250 mg Oral

Indications

non-small cell lung carcinoma